Swiss/NNP Healthcare/NNP Group/NNP Plans/VBZ to/TO Launch/NNP Aids-fighting/NNP Drug/NNP The/DT Swiss/JJ healthcare/NN group/NN Roche/NNP plans/VBZ to/TO launch/VB a/DT new/JJ Aids/NNP treatment/NN drug/NN for/IN patients/NNS who/WP fail/VBP to/TO respond/VB to/TO conventional/JJ therapy/NN ,/, the/DT company/NN 's/POS chairman/NN said/VBD on/IN Wednesday/NNP ./.

The/DT drug/NN ,/, named/VBN T-20/JJ ,/, is/VBZ being/VBG developed/VBN with/IN the/DT United/NNP States/NNP biotech/JJ firm/NN Trimeris/NNP Inc./NNP ,/, and/CC is/VBZ expected/VBN to/TO be/VB available/JJ in/IN 2003/CD ./.

Roche/NNP chairman/NN Franz/NNP Humer/NNP said/VBD he/PRP anticipates/VBZ that/IN it/PRP will/MD gain/VB approval/NN in/IN the/DT United/NNP States/NNPS and/CC Europe/NNP ,/, and/CC would/MD later/RB be/VB more/RBR widely/RB used/VBN ./.

``/`` If/IN the/DT data/NNS is/VBZ good/JJ ,/, I/PRP would/MD expect/VB a/DT rather/RB rapid/JJ approval/NN for/IN such/PDT a/DT drug/NN ,/, ''/'' Humer/NNP said/VBD ./.

T-20/NN is/VBZ the/DT first/JJ of/IN a/DT new/JJ class/NN of/IN anti-HIV/JJ drugs/NNS called/VBN fusion/NN inhibitors/NNS ,/, which/WDT are/VBP designed/VBN to/TO prevent/VB the/DT Aids-causing/JJ virus/NN from/IN penetrating/VBG the/DT body/NN 's/POS cells/NNS ./.

Unlike/IN many/JJ HIV/NN medicines/NNS ,/, T-20/NN must/MD be/VB injected/VBN ,/, rather/RB than/IN taken/VBN as/IN a/DT pill/NN ./.

The/DT new/JJ drug/NN represents/VBZ a/DT new/JJ approach/NN in/IN that/WDT it/PRP is/VBZ designed/VBN to/TO prevent/VB HIV/NN from/IN fusing/NN with/IN human/JJ cells/NNS ./.

It/PRP represents/VBZ a/DT significant/JJ stride/NN in/IN fighting/VBG the/DT constantly/RB mutating/JJ virus/NN ./.

